Sinew Pharma (ROCO:6634) EBITDA Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6634 Sinew Pharma Inc ROCO:6634
25 GF Score
Price NT$60.10
! 2 Warning Signs
View Full Analysis

What is Sinew Pharma EBITDA Margin %?

Sinew Pharma ROCO:6634 +0.17% 25 EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus rates ROCO:6634 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Sinew Pharma ranks worse than 98.62% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sinew Pharma's EBITDA for the six months ended in Jun. 2026 was NT$-53.85 Mil. Sinew Pharma's Revenue for the six months ended in Jun. 2026 was NT$0.00 Mil. Therefore, Sinew Pharma's EBITDA margin for the quarter that ended in Jun. 2026 was 0.00%.

Sinew Pharma  (ROCO:6634) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Sinew Pharma EBITDA Margin % Related Terms

Sinew Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Sinew Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinew Pharma EBITDA Margin % Chart

Sinew Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,104.27 -35,698.78 0.00 0.00 -220,759.57

Sinew Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ROCO:6634 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison

For the Biotechnology subindustry, Sinew Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinew Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinew Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sinew Pharma's EBITDA Margin % falls into.


ROCO:6634
25GF Score
Sinew Pharma Inc ROCO:6634
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinew Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sinew Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-103.757/0.047
=-220,759.57 %

Sinew Pharma's EBITDA Margin % for the quarter that ended in Jun. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-53.852/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Sinew Pharma (ROCO:6634) has a EBITDA Margin % of 0.00% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinew Pharma and its competitors. According to the industry distribution chart, Sinew Pharma ranks #929 out of 942 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Sinew Pharma's EBITDA Margin % too high?
Sinew Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Sinew Pharma ranks #929 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sinew Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Sinew Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinew Pharma ranks #929 out of 942 companies for EBITDA Margin %. This places Sinew Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinew Pharma and its competitors. Sinew Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinew Pharma stock overvalued right now?
Sinew Pharma (ROCO:6634) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Sinew Pharma's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sinew Pharma (ROCO:6634), the current EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinew Pharma Business Description

Address Xueyin Road, Lane 130, Section 1, C516, Building C, Number 99, Nangang District, Taipei, TWN, 11571
Sinew Pharma Inc is a Taiwan-based biopharmaceutical company. The company is mainly engaged in the research and development of new drugs for the treatment of liver diseases and pain relief. Its drug candidates includes SNP-610, SNP-630, SNP-810, SNP-820, SNP-830 and SNP-840.
25GF Score

Get the complete analysis for ROCO:6634

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$60.10
Price